Waters Corporation
WAT Large CapHealthcare · Diagnostics & Research
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Waters Corporation en bref
Waters Corporation (WAT) is currently trading at 309,86 € with a market capitalization of 30,4 Md €. The trailing P/E ratio stands at 45.22x, with a forward P/E of 21.6x. The 52-week range spans from 239,78 € to 361,04 €; the current price is 14.2% below the yearly high. Year-over-year revenue growth stands at +91.4%. The net profit margin stands at 11.93%.
💰 Dividende
Waters Corporation currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
22 analystes évaluent Waters Corporation (WAT) au consensus : Acheter. L'objectif de cours moyen est de 348,94 €, soit un potentiel de +12.61% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 300,76 € à 401,01 €.
Waters Corporation : la thèse d'investissement en détail
Waters Corporation (WAT) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 91.4% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind.
Le scénario baissier
Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.
Valorisation en contexte
The EV/EBITDA multiple of 35.72x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.
À surveiller
- The forward P/E of 21.6x is meaningfully below the trailing 45.22x — analysts expect earnings to step up; the next earnings release is the test.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 91.4% sur un an
- Marge brute élevée de 55.15% — signe d'un pouvoir de fixation des prix
- Consensus des analystes : Buy
- Bilan solide avec faible endettement (D/E 36.63)
- –Actuellement jugée surévaluée
- –Free cash flow négatif
Aperçu technique
The price is in a transition zone relative to the moving averages — no clear signal.
Profil de risque
The data points to market-like volatility.
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Waters Corporation?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news
